Comparative secretome analysis of cholangiocarcinoma cell line in three-dimensional culture

International Journal of Oncology

Volumn 45, Issue 5, 2014, Pages 2108-2116

  Tit Oon, Phanthakarn ^a   Chokchaichamnankit, Darane ^b   Khongmane, Amnart ^a   Sawangaretrakul, Phane ^b   Svasti, Jisnuson ^a,b   Srisomsap, Chantragan ^b  

^a Research and Innovation   (Thailand)

^b Krung Thep Maha Nakhon   (Thailand)

Author keywords

Cancer; Cholangiocarcinoma; Proteomics; Secretome; Three dimensional culture

Indexed keywords

ALPHA ENOLASE; CELL PROTEIN; COLLAGEN; PHOSPHOGLYCERATE MUTASE; SECRETOME; TRIOSEPHOSPHATE ISOMERASE; UNCLASSIFIED DRUG; CULTURE MEDIUM; PROTEOME; TUMOR PROTEIN;

ARTICLE; BILE DUCT CARCINOMA; CANCER CELL LINE; CANCER GROWTH; CELL CULTURE; IMMUNOBLOTTING; MONOLAYER CULTURE; NUCLEOTIDE SEQUENCE; PROTEIN ANALYSIS; PROTEIN SECRETION; THREE DIMENSIONAL CELL CULTURE; BIOSYNTHESIS; CULTURE MEDIUM; CULTURE TECHNIQUE; GENETICS; HUMAN; LIVER CELL CARCINOMA; LIVER TUMOR; PATHOLOGY; SECRETION (PROCESS); TANDEM MASS SPECTROMETRY; TUMOR MICROENVIRONMENT;

CARCINOMA, HEPATOCELLULAR; CELL CULTURE TECHNIQUES; CHOLANGIOCARCINOMA; CULTURE MEDIA, CONDITIONED; HUMANS; LIVER NEOPLASMS; NEOPLASM PROTEINS; PROTEOME; TANDEM MASS SPECTROMETRY; TUMOR MICROENVIRONMENT;

EID: 84907202577     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2014.2636     Document Type: Article

References (36)

1. K han SA, Thomas HC, Davidson BR and Taylor-Robinson SD: Cholangiocarcinoma. Lancet 366: 1303-1314, 2005.
2. K han SA, Toledano MB and Taylor-Robinson SD: Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma. HPB 10: 77-82, 2008.
3. Sripa B, Kaewkes S, Sithithaworn P, et al: Liver fluke induces cholangiocarcinoma. PLoS Med 4: E201, 2007.
4. Leelawat K, Narong S, Wannaprasert J and Ratanashu-ek T: Prospective study of MMP7 serum levels in the diagnosis of cholangiocarcinoma. World J Gastroenterol 16: 4697-4703, 2010.
5. Mott JL and Gores GJ: Targeting IL-6 in cholangiocarcinoma therapy. Am J Gastroenterol 102: 2171-2172, 2007.
6. Shigehara K, Yokomuro S, Ishibashi O, et al: Real-time PCR-based analysis of the human bile microRNAome identifies miR-9 as a potential diagnostic biomarker for biliary tract cancer. PLoS One 6: E23584, 2011.
7. Makridakis M and Vlahou A: Secretome proteomics for discovery of cancer biomarkers. J Proteomics 73: 2291-2305, 2010.
8. Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al: Proteomic analysis of cholangiocarcinoma cell line. Proteomics 4: 1135-1144, 2004.
9. Srisomsap C, Sawangareetrakul P, Subhasitanont P, et al: Proteomic studies of cholangiocarcinoma and hepatocellular carcinoma cell secretomes. J Biomed Biotechnol 2010: 437143, 2010.
10. Hutmacher DW, Loessner D, Rizzi S, Kaplan DL, Mooney DJ and Clements JA: Can tissue engineering concepts advance tumor biology research? Trends Biotechnol 28: 125-133, 2010.
11. Pampaloni F, Reynaud EG and Stelzer EH: The third dimension bridges the gap between cell culture and live tissue. Nat Rev Mol Cell Biol 8: 839-845, 2007.
12. Yamada KM and Cukierman E: Modeling tissue morphogenesis and cancer in 3D. Cell 130: 601-610, 2007.
13. W eigelt B and Bissell MJ: The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev 69-70: 42-51. 2014.
14. Sirisinha S, Tengchaisri T, Boonpucknavig S, Prempracha N, Ratanarapee S and Pausawasdi A: Establishment and characterization of a cholangiocarcinoma cell line from a Thai patient with intrahepatic bile duct cancer. Asian Pac J Allergy Immunol 9: 153-157, 1991.
15. Laohathai K and Bhamarapravati N: Culturing of human hepatocellular carcinoma. A simple and reproducible method. Am J Pathol 118: 203-208, 1985.
16. W eeraphan C, Diskul-Na-Ayudthaya P, Chiablaem K, et al: Effective enrichment of cholangiocarcinoma secretomes using the hollow fiber bioreactor culture system. Talanta 99: 294-301, 2012.
17. Pruksakorn D, Lirdprapamongkol K, Chokchaichamnankit D, et al: Metabolic alteration of HepG2 in scaffold-based 3-D culture: Proteomic approach. Proteomics 10: 3896-3904, 2010.
18. K hongmanee A, Lirdprapamongkol K, Tit-oon P, Chokchaichamnankit D, Svasti J and Srisomsap C: Proteomic analysis reveals important role of 14-3-3sigma in anoikis resistance of cholangiocarcinoma cells. Proteomics 13: 3157-3166, 2013.
19. Cardinale V, Carpino G, Reid L, Gaudio E and Alvaro D: Multiple cells of origin in cholangiocarcinoma underlie biological, epidemiological and clinical heterogeneity. World J Gastrointest Oncol 4: 94-102, 2012.
20. Chiarini LB, Takiya CM, Borojevic R and Monteiro AN: Long-term culture of cholangiocytes from liver fibro-granulomatous lesions. BMC Gastroenterol 6: 13, 2006.
21. Mall AS, Tyler MG, Ho SB, et al: The expression of MUC mucin in cholangiocarcinoma. Pathol Res Pract 206: 805-809, 2010.
22. Haeuptle MT, Suard YL, Bogenmann E, Reggio H, Racine L and Kraehenbuhl JP: Effect of cell shape change on the function and differentiation of rabbit mammary cells in culture. J Cell Biol 96: 1425-1434, 1983.
23. Perathoner A, Pirkebner D, Brandacher G, et al: 14-3-3sigma expression is an independent prognostic parameter for poor survival in colorectal carcinoma patients. Clin Cancer Res 11: 3274-3279, 2005.
24. Zhou WH, Tang F, Xu J, et al: Aberrant upregulation of 14-3-3s expression serves as an inferior prognostic biomarker for gastric cancer. BMC Cancer 11: 397, 2011.
25. Santini MT, Rainaldi G, Romano R, et al: MG-63 human osteosarcoma cells grown in monolayer and as three-dimensional tumor spheroids present a different metabolic profile: A (1)H NMR study. FEBS Lett 557: 148-154, 2004.
26. Thongwatchara P, Promwikorn W, Srisomsap C, Chokchaichamnankit D, Boonyaphiphat P and Thongsuksai P: Differential protein expression in primary breast cancer and matched axillary node metastasis. Oncol Rep 26: 185-191, 2011.
27. Yoshida A, Okamoto N, Tozawa-Ono A, et al: Proteomic analysis of differential protein expression by brain metastases of gynecological malignancies. Hum Cell 26: 56-66, 2013.
28. Ren F, Wu H, Lei Y, et al: Quantitative proteomics identification of phosphoglycerate mutase 1 as a novel therapeutic target in hepatocellular carcinoma. Mol Cancer 9: 81, 2010.
29. Yonglitthipagon P, Pairojkul C, Bhudhisawasdi V, Mulvenna J, Loukas A and Sripa B: Proteomics-based identification of alphaenolase as a potential prognostic marker in cholangiocarcinoma. Clin Biochem 45: 827-834, 2012.
30. Shinomiya H: Plastin family of actin-bundling proteins: Its functions in leukocytes, neurons, intestines, and cancer. Int J Cell Biol 2012: 213492, 2012.
31. K ang S, Shim HS, Lee JS, et al: Molecular proteomics imaging of tumor interfaces by mass spectrometry. J Proteome Res 9: 1157-1164, 2010.
32. Ang CS and Nice EC: Targeted in-gel MRM: A hypothesis driven approach for colorectal cancer biomarker discovery in human feces. J Proteome Res 9: 4346-4355, 2010.
33. Lin CS, Park T, Chen ZP and Leavitt J: Human plastin genes. Comparative gene structure, chromosome location, and differential expression in normal and neoplastic cells. J Biol Chem 268: 2781-2792, 1993.
34. Park T, Chen ZP and Leavitt J: Activation of the leukocyte plastin gene occurs in most human cancer cells. Cancer Res 54: 1775-1781, 1994.
35. Saenz-Lopez P, Carretero R, Vazquez F, et al: Impact of interleukin-18 polymorphisms-607 and -137 on clinical characteristics of renal cell carcinoma patients. Hum Immunol 71: 309-313, 2010.
36. Tangkijvanich P, Thong-Ngam D, Mahachai V, Theamboonlers A and Poovorawan Y: Role of serum interleukin-18 as a prognostic factor in patients with hepatocellular carcinoma. World J Gastroenterol 13: 4345-4349, 2007.